πŸ‡ΊπŸ‡Έ FDA
Patent

US 9833508

Cancer therapeutics

granted A61KA61K31/12A61K31/713

Quick answer

US patent 9833508 (Cancer therapeutics) held by IMMIX BIOPHARMA, INC. expires Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
IMMIX BIOPHARMA, INC.
Grant date
Tue Dec 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/12, A61K31/713, A61K39/3955, A61K47/6849